drugset / Trial / NCT00809783

Extension Study Of Tanezumab In Osteoarthritis

NCT00809783

Phase 3 Terminated 2147 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab

Timeline

Start
2009-02-06
Primary completion
2010-11-02
Completion
2011-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Tanezumab Monoclonal antibody 2.5 mg
Subject Tanezumab Monoclonal antibody 5 mg
Subject Tanezumab Monoclonal antibody 10 mg

Indications